Figure 2 Signalling pathways and physiological domains that are

Slides:



Advertisements
Similar presentations
HDAC6 : HDAC6 is a cytoplasmic enzyme that regulates many important biological processes. : HDAC6 has recently emerged as a tubulin deacetylase that has.
Advertisements

Bmi-1 in Cancer Cancer genetics 2012/04/ 전종철
Chapter 9 Cell Cycle and Cancer. Figure 17-1 Molecular Biology of the Cell (© Garland Science 2008) Cell Cycle.
Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Targeting the DNA Damage Response in Cancer
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation  Roland Hubaux, PhD, Kelsie L. Thu, BSc, Bradley.
Adverse Renal Effects of Immune Checkpoint Inhibitors:
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Discussion Outline Cells of the Immune System.
Figure 2 Multiscale modelling in oncology
Figure 1 Cellular processes involved in cancer development
Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Figure 2 Neoantigen presentation in the tumour microenvironment
Figure 1 Four nodes to target when inducing anti-tumour immunity
Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2
Nat. Rev. Clin. Oncol. doi: /nrclinonc
B lymphocytes produce antibodies.
Figure 7 Clinical options for HCC therapy
Figure 1 Classical and non-classical models of the cell cycle in RB1-proficient cells Figure 1 | Classical and non-classical models of the cell cycle in.
Figure 3 The cell cycle and the role of CDK4/6 inhibition
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Oncology Meets Immunology: The Cancer-Immunity Cycle
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Possible combination therapies CDK4/6 inhibitors
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Gerard L. Brien, Daria G. Valerio, Scott A. Armstrong  Cancer Cell 
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 A schematic representation of the HER2 signalling pathway
Figure 4 Combination immunotherapeutic approaches with imatinib
Volume 56, Issue 3, Pages (March 2012)
Nat. Rev. Urol. doi: /nrurol
Figure 1 Putative anticancer mechanisms of action of PARP inhibitors
Nat. Rev. Urol. doi: /nrurol
Figure 4 Macrophage-targeting antitumour treatment approaches
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 mTOR complex biology
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 The yin and yang of tumour-associated
Figure 5 The mechanism underlying epithelial-to-mesenchymal
Figure 1 The role of CTLA4 and PD1 in T cell activation
Figure 2 Approaches to improve CAR-T-cell therapy
Figure 2 Site of action of checkpoint inhibitors and agonists being
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway
Mechanism of CTLA-4-induced immunosuppression.
Nat. Rev. Endocrinol. doi: /nrendo
Nat. Rev. Urol. doi: /nrurol
Figure 1 Main triggers of senescence
MicroRNA Control in the Immune System: Basic Principles
Figure 1 Mechanisms of action of immunotherapy modalities
Nat. Rev. Urol. doi: /nrurol
Genome Regulation by Polycomb and Trithorax Proteins
Figure 2 Histone acetylation regulates gene expression
Martin Sauvageau, Guy Sauvageau  Cell Stem Cell 
Cell-mediated immunity Regulation of the immune response
Nat. Rev. Rheumatol. doi: /nrrheum
Padmanee Sharma, James P. Allison  Cell 
Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.
Figure 4 Molecular signalling and immunological
Immunity and the Animation of the Genome
(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
Presentation transcript:

Figure 2 Signalling pathways and physiological domains that are the focus of experimental targeted therapies for small-cell lung cancer (SCLC) Figure 2 | Signalling pathways and physiological domains that are the focus of experimental targeted therapies for small-cell lung cancer (SCLC). a | Dashed and solid lines indicate indirect and direct interactions, respectively. Proteins in green are typically upregulated in SCLCs compared with nonmalignant lung tissue, while those in red are downregulated or absent. Examples of the investigational molecularly targeted agents or antibody-based treatments targeting each signalling node are provided. b | The novel, investigational, targeted therapeutics for SCLC are predicated on five aspects of cancer biology. Immune-checkpoint blockade with antibodies targeting programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and/or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can prime the adaptive immune response to SCLC cells, whereas antibody-mediated blockade of the 'don't eat me' protein CD47 can enable phagocytosis of tumour cells by macrophages. The use of small-molecule inhibitors of key regulators of the cell cycle, such as the protein kinases WEE1 and aurora kinase A, exploits the inherent lack of the G1/S-checkpoint activity resulting from loss of the tumour suppressors p53 and retinoblastoma-associated protein (Rb) in most SCLC cells. WEE1 regulates the G2/M cell-cycle checkpoint that is essential for ensuring the integrity of the genome in such cancer cells and, thus, inhibition of this kinase can lead to mitotic catastrophe and apoptosis, particularly if combined with DNA-damaging therapies. By contrast, aurora kinase A has essential roles in mitosis, and inhibitors of this protein results in cell-cycle arrest, preventing cell proliferation. Inhibitors of Notch have demonstrated antitumour effects in preclinical studies. Moreover, Delta-like protein 3 (DLL3), an inhibitory Notch ligand, is specifically upregulated in SCLC and can, therefore, be leveraged for selective tumour targeting with the antibody–drug conjugate rovalpituzumab tesirine (Rova-T). Inhibitors of the histone-lysine N-methyltransferase EZH2 (also known as enhancer of zeste homologue 2), the enzymatic histone-lysine N-methyltransferase subunit of the polycomb repressive complex 2 (PRC2) chromatin-remodelling machinery, can prevent chemoresistance and cell proliferation by counteracting epigenetic gene silencing, in particular, of schlafen family member 11 (SLFN11) — a protein that negatively regulates homologous recombination DNA repair. Poly [ADP-ribose] polymerase (PARP) inhibitors prevent the activation of DNA-repair proteins by PARP1 and trap this enzyme on DNA, which causes further DNA damage that can eventually result in cell death. APC, antigen-presenting cell; ASCL1, achaete-scute homologue 1 (also known as ASH-1); Chk1/2, checkpoint kinase 1/2; E2F1, transcription factor E2F1 (also known as retinoblastoma-associated protein 1); PAR, poly-ADP-ribosylation. Sabari, J. K. et al. (2017) Unravelling the biology of SCLC: implications for therapy Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.71